Does Humana Cover Jatenzo?

What Is Jatenzo and Why Does Coverage Get Complicated?

Jatenzo is the first oral testosterone undecanoate approved by the FDA for adult males with primary or hypogonadotropic hypogonadism [1]. The capsule is absorbed via the lymphatic system, which means it bypasses first-pass hepatic metabolism and avoids the liver-toxicity signal associated with older oral androgens like methyltestosterone [2]. Because it is a branded specialty drug with a list price near $900 per month and no generic equivalent, insurers treat it differently from injectable testosterone cypionate, which costs roughly $30 to $60 per month at most pharmacies.

Coverage is further complicated by two classification problems. First, some Humana utilization-management teams initially code Jatenzo requests under weight-loss or body-composition categories, triggering automatic denials under CMS rules that bar coverage of weight-loss drugs on Medicare Advantage plans [3]. Jatenzo is not indicated for weight loss. It is indicated for hypogonadism, and this misclassification is the single most correctable error in the appeal process. Second, because the drug is newer than established testosterone formulations, many Humana formularies placed it on a non-preferred specialty tier at launch and have not updated that placement since.

The clinical rationale for oral testosterone is real. In the key phase 3 trial by Swerdloff et al. (N=166 hypogonadal men), Jatenzo titrated between 158 mg and 237 mg twice daily produced serum testosterone levels within the normal range (300 to 1 to 050 ng/dL) in 87% of subjects over 90 days [4]. Mean total testosterone rose from a baseline of 216 ng/dL to 462 ng/dL at day 90. These are not marginal effects. A patient whose insurer denies coverage must understand that a strong clinical record exists to support the prescription.

Humana Commercial Plan Coverage: What to Expect

Humana commercial formularies (employer-sponsored and individual market plans) do not share a single national drug list, so the specific tier and PA criteria depend on the plan ID printed on the member's card [5]. Across the major 2024 Humana commercial formulary structures, Jatenzo most commonly appears as a Tier 4 or Tier 5 non-preferred specialty drug. That placement means the member's cost-share is highest before meeting the deductible and may remain $200 or more per fill even after [6].

Prior authorization is nearly universal for Jatenzo on commercial plans. The standard Humana commercial PA criteria for testosterone products generally require:

• A documented diagnosis of hypogonadism (ICD-10 E29.1 for primary, E23.0 for hypogonadotropic)
• At least two fasting morning serum testosterone levels below 300 ng/dL, drawn on separate days
• Documentation that symptoms consistent with hypogonadism are present (reduced libido, fatigue, decreased muscle mass, etc.)
• A statement of why the prescribing clinician selected Jatenzo over a less expensive testosterone formulation, or documented failure or intolerance of a preferred agent

That last criterion introduces step therapy. Humana commercial plans frequently list testosterone cypionate injection or a generic testosterone gel as preferred alternatives [7]. If the patient has not tried one of those agents, the PA reviewer may deny Jatenzo as "not medically necessary compared to available preferred alternatives." Documenting a clinical reason for bypassing injectables (needle phobia, compliance history, skin-transfer risk with topicals in a household with women or children) strengthens the PA submission materially.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We suggest testosterone therapy for men with hypogonadism to induce and maintain secondary sex characteristics and to improve their sexual function, body composition, bone mineral density, mood, and quality of life" [8]. Quoting that language in the PA letter, paired with the patient's specific symptom burden and two confirmatory testosterone levels, covers the essential documentation checklist.

Humana Medicare Advantage Coverage: A Harder Path

Medicare Advantage plans sold by Humana must follow CMS formulary guidelines, and those guidelines create two overlapping problems for Jatenzo [3].

The first problem: Medicare Part D does not cover drugs used for weight gain or weight loss except in narrow circumstances. Some Humana MA plan pharmacy benefit managers have incorrectly categorized testosterone therapy under this exclusion, treating it as a body-composition drug rather than a hormone-replacement drug. That error is appealable. The correct CMS coding for testosterone in a diagnosed male hypogonadism patient is a covered Part D category [9].

The second problem: even when coded correctly, Jatenzo may simply not appear on a given Humana MA plan's formulary. CMS requires Part D plans to cover at least two drugs per therapeutic category, and most MA plans satisfy the testosterone category with injectable testosterone or a generic topical. A branded oral capsule costing ten times more may be excluded entirely, or placed on a "non-formulary" status requiring a formulary exception before any coverage determination can proceed [10].

Formulary exception requests for Medicare Advantage follow a specific pathway. The prescribing physician must submit a "coverage determination request" to Humana, stating that the formulary alternatives are not clinically appropriate for this specific patient. Humana is then required by CMS to respond within 72 hours for standard requests and 24 hours for expedited requests when the standard timeframe would seriously jeopardize the enrollee's health [11]. Approval rates for formulary exceptions are plan-specific, but nationally about 37% of Part D formulary exception requests are granted at the initial determination stage [12].

Prior Authorization Criteria for Jatenzo on Humana Plans

The specific PA criteria vary by plan year and by whether the plan is commercial or Medicare Advantage, but the following framework covers the requirements that appear across Humana's published coverage policies and utilization-management vendor criteria [13].

Diagnosis documentation required:

• ICD-10 code for male hypogonadism (E29.1 primary or E23.0 secondary/hypogonadotropic)
• Two morning serum total testosterone measurements below 300 ng/dL (some policies specify <300 ng/dL on two separate occasions at least one week apart)
• Free testosterone may be requested if total testosterone is borderline

Clinical workup required:

• LH and FSH levels to differentiate primary from secondary hypogonadism
• Hematocrit/hemoglobin at baseline (Jatenzo carries an FDA boxed warning about blood pressure elevation and a label warning about polycythemia) [1]
• PSA and digital rectal exam documentation for men age 40 or older

Step therapy or preferred agent failure:

• Documentation that the prescriber considered generic testosterone cypionate injection and/or a generic testosterone gel
• OR a clinical justification for bypassing those agents (skin-transfer risk, injection site complications, documented compliance failure, patient-specific pharmacokinetic rationale)

Blood pressure documentation:

• Jatenzo's FDA label requires blood pressure assessment before initiation because the drug raised systolic blood pressure by 3 to 5 mmHg in clinical trials [1]. Humana PA criteria often include baseline BP and a note on cardiovascular risk management [14].

A PA submission that addresses every item on this list in a single organized letter, with lab reports attached, moves through review faster and with fewer information requests.

Step Therapy Requirements: Which Agents Come First?

Step therapy is a coverage mechanism that requires a patient to try and fail a preferred drug before the plan covers the requested drug. For Jatenzo, Humana commercial plans commonly require at least one step, and some require two [7].

Step 1 (most common requirement): Generic testosterone cypionate injection, typically 100 to 200 mg intramuscularly every one to two weeks, is the most common required first-line agent. It costs roughly $30 to $60 per month at major pharmacies and is on virtually every formulary's preferred tier.

Step 2 (some plans): A generic testosterone gel (1% or 1.62%, generic versions of AndroGel) or a testosterone patch may be required as a second step if the patient cannot tolerate injections.

Bypassing step therapy: Federal law (the Restoring the Patient's Voice Act provisions embedded in many state insurance codes) and CMS rules allow prescribers to request a step therapy exception when the required step agents are contraindicated, previously failed, or clinically inappropriate [15]. Written documentation of the exception request should specify the clinical reason. "Patient prefers oral route" alone is usually insufficient. "Patient has documented needle phobia per DSM-5 criteria" or "patient lives with a female partner of childbearing age and topical transfer risk was discussed and deemed unacceptable" are more likely to succeed.

How to Appeal a Humana Denial of Jatenzo

Denials are not final. Humana's own appeals data, consistent with industry-wide figures, show that roughly 40 to 60% of appealed PA denials for specialty drugs are reversed at the first level of internal appeal [16]. The steps are sequential and have hard deadlines.

Step 1: Internal appeal (Level 1 grievance) File within 60 days of receiving the denial notice for commercial plans. For Medicare Advantage, the deadline is 60 days from the notice. Include a physician letter addressing the denial reason specifically, updated lab work if the original was older than 90 days, and the clinical guideline citation from the Endocrine Society or American Urological Association supporting the prescription [8].

Step 2: External independent review If Humana upholds the denial at Step 1, commercial plan members in most states can request an independent medical review (IMR) through their state insurance commissioner's office. The independent reviewer is not employed by Humana and reversal rates at this stage are often higher than at internal review.

Step 3: MAXIMUS Federal Services (Medicare Advantage) Medicare Advantage denials that survive Humana's internal appeal go to MAXIMUS Federal Services, the CMS-contracted independent review entity. MAXIMUS has 14 days for standard reviews and 72 hours for expedited reviews [11]. The prescriber must submit a clinical brief explaining why Jatenzo is medically necessary for this patient and why formulary alternatives are not clinically equivalent. Citing the Swerdloff 2020 trial data showing 87% of patients achieving normal serum testosterone on the titrated oral dose [4] and noting that this patient cannot use the formulary alternative with specific documented reasons is the strongest package.

Step 4: Administrative Law Judge hearing If the MAXIMUS decision is adverse and the amount in controversy exceeds $180 (2024 threshold), the member or provider may request an ALJ hearing before the Office of Medicare Hearings and Appeals. This step is rarely necessary for a single prescription but may be worth pursuing for a patient who needs the drug long-term.

The Humana member services number for pharmacy appeals is on the back of the insurance card. The Medicare Advantage grievance and appeals line is separate from the commercial line and must be used for MA plan disputes.

Can You Use the Jatenzo Manufacturer Savings Card With Humana?

Clarus Therapeutics (the Jatenzo manufacturer) has offered a copay savings program for commercially insured patients. The program typically reduces out-of-pocket cost to near zero for eligible patients with commercial insurance [17]. Eligibility conditions that disqualify a patient include:

• Enrollment in Medicare, Medicaid, TRICARE, or any other federal or state government insurance program
• Residence in certain states with specific regulations on manufacturer copay programs
• Plans that have implemented copay accumulator programs (many Humana commercial plans have done this, meaning the manufacturer's payment does not count toward the member's deductible)

The copay accumulator issue is material. Humana implemented copay accumulator adjustment programs on many of its commercial formularies beginning in plan year 2022 [18]. Under these programs, the manufacturer savings card still pays the copay at the pharmacy counter, but Humana does not apply that payment toward the member's annual deductible or out-of-pocket maximum. The member continues to owe full cost-sharing until they meet the deductible from their own funds. Patients should confirm their plan's accumulator policy before assuming the savings card resolves their affordability problem.

Medicare Advantage patients cannot use manufacturer savings cards under federal Anti-Kickback Statute rules [19]. For these patients, the Jatenzo list price of approximately $900 per month is the cash baseline if coverage is denied and no other assistance is available.

What Humana's Formulary Exclusion of Jatenzo Means for Patients

A formulary exclusion is different from a prior authorization denial. A PA denial means the drug is on the formulary but the plan is not approving coverage for this patient's specific request. A formulary exclusion means the drug is not on the plan's drug list at all, and no PA approval is possible without first obtaining a formulary exception [10].

For Jatenzo on Humana Medicare Advantage plans specifically, exclusion is more common than PA denial. The patient or provider must first establish that Jatenzo is medically necessary and that no formulary alternative is clinically appropriate before a standard PA process even begins. This two-step process (formulary exception followed by PA) takes longer and requires more documentation.

If a formulary exception is denied, the member can appeal that denial using the same MAXIMUS pathway described above. The clinical argument is the same: Jatenzo is the appropriate drug for this patient, and the formulary alternatives are not clinically equivalent for a stated and documented reason.

Alternative Coverage Pathways if Humana Will Not Cover Jatenzo

If the appeal process is exhausted and Humana still will not cover Jatenzo, three practical alternatives exist.

Cash pay with manufacturer assistance: For commercially insured patients who exhaust their appeal, the manufacturer savings program may still apply. The drug's cash price at most pharmacies is near the list price of $900 per month, but some specialty pharmacy programs and telehealth platforms can arrange lower negotiated cash prices [17].

Switch to a covered testosterone formulation: Injectable testosterone cypionate at 100 to 200 mg every one to two weeks is effective, well-studied, and costs $30 to $60 per month. If oral delivery is not a clinical necessity, the cost-benefit calculus often favors switching. The Endocrine Society guideline notes that no single testosterone formulation is superior in efficacy; the choice is driven by patient preference, pharmacokinetics, and safety profile [8].

Plan change at open enrollment: If the patient is on a Medicare Advantage plan that excludes Jatenzo and the drug is medically important, switching to a different MA plan or to Original Medicare plus a Part D plan that includes Jatenzo may be the most durable solution. The Medicare Plan Finder tool at cms.gov allows drug-specific formulary searches before enrollment [20].

Patient assistance program: Clarus Therapeutics has offered a patient assistance program for uninsured or underinsured patients who meet income criteria [17]. Eligibility and availability change annually and must be confirmed directly with the manufacturer.

Blood Pressure and Safety Considerations That Affect Coverage Letters

Jatenzo carries an FDA boxed warning about the potential for increases in blood pressure, and the label states that cardiovascular risk should be evaluated before prescribing [1]. In the key Swerdloff trial, mean systolic blood pressure increased by approximately 4 to 5 mmHg from baseline [4]. The FDA required a Risk Evaluation and Mitigation Strategy (REMS) communication about this finding, and prescribers must counsel patients accordingly [21].

This safety data shows up in coverage denials in one specific way. Some Humana clinical reviewers cite the blood pressure boxed warning as a reason to deny Jatenzo in favor of topical testosterone, which lacks that same label warning. A physician appeal letter should address this directly: the blood pressure signal is real, the patient's baseline BP is documented, and the prescriber has a management plan in place. Leaving that issue unaddressed hands the reviewer a reason to uphold the denial.

The American Heart Association has noted that testosterone therapy in general carries cardiovascular signals that require individualized risk assessment before prescribing [22]. Documenting that assessment in the PA letter (baseline BP, cardiovascular history, 10-year ASCVD risk score) signals clinical rigor and tends to reduce reviewer pushback.